Survodutide vs Retatrutide
Dual GLP-1/glucagon against the triple agonist that adds GIP.
The short answer: Both act on glucagon and GLP-1; only retatrutide also targets GIP.
Survodutide
Retatrutide
Side by side
| Property | Survodutide | Retatrutide |
|---|---|---|
| Research category | Metabolic Research | Metabolic Research |
| Presentation | 5mg vial | 4mg × 4 pens |
| Dosage options | 5mg · 10mg | 4mg × 4 pens · 8mg × 4 pens · 12mg × 4 pens |
| Approved medicine using it | None — investigational | None — investigational |
| Availability | In stock | In stock |
| Batch COA | Supplied with order | Supplied with order |
| From | €324.90 | €357.90 |
How they differ
Survodutide is a dual GLP-1 and glucagon receptor agonist. Retatrutide targets those same two receptors and adds GIP, making it the more complete of the two mechanistically.
That makes this the cleanest pairing in the catalogue for isolating the GIP contribution: the two compounds are otherwise mechanistically similar, so the difference between them is largely attributable to that third receptor.
Both remain investigational, and neither has a marketed brand.
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use. Brand names are trademarks of their respective owners and are referenced only to identify the active compound — no affiliation or equivalence is claimed.